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license (http://creativecommons.org/Summary Large bone defects are serious complications that are most commonly caused by
extensive trauma, tumour, infection, or congenitalmusculoskeletal disorders. If nonunion occurs,
implantation for repairing bone defects with biomaterials developed as a defect filler, which can
promote bone regeneration, is essential. In order to evaluate biomaterials to be developed as
bone substitutes for bone defect repair, it is essential to establish clinically relevant in vitro
and in vivo testing models for investigating their biocompatibility, mechanical properties, degra-
dation, and interactional with culture medium or host tissues. The results of the in vitro experi-
ment contribute significantly to the evaluation of direct cell response to the substitute
biomaterial, and the in vivo tests constitute a stepmidway between in vitro tests and human clin-
ical trials. Therefore, it is essential to develop or adopt a suitable in vivo bone defect animal
model for testing bone substitutes for defect repair. This reviewaimed at introducing and discuss-
ing the most available and commonly used bone defect animal models for testing specific substi-
tute biomaterials. Additionally, we reviewed surgical protocols for establishing relevant
preclinical bone defect models with various animal species and the evaluation methodologies
of the bone regeneration process after the implantation of bone substitute biomaterials. This re-
view provides an important reference for preclinical studies in translational orthopaedics.
Copyright ª 2015, The Authors. Published by Elsevier (Singapore) Pte Ltd. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Translational Medicine Research and Development, Shenzhen Institutes of Advanced Technology,
ueyuan Avenue, Shenzhen University Town, Shenzhen 518055, China.
.cn (X.-L. Wang), yx.lai@siat.ac.cn (Y.-X. Lai).
05.002
hors. Published by Elsevier (Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND
licenses/by-nc-nd/4.0/).
96 Y. Li et al.Introduction
Bone defect healing is a process of reconstruction of the
bone tissue, which generally undergoes a multidimensional
procedure with an overlapping timeline [1]. The vast ma-
jority of bone defects can heal spontaneously under suitable
physiological environmental conditions due to the regener-
ation ability of bone. However, the healing process of bone
defect is time consuming, and new bone generation takes
place slowly because of decreased blood supply to the
fracture site and insufficiency of calcium and phosphorus to
strengthen and harden new bone. In addition, large defects,
also known as critical bone defects, may not heal sponta-
neously and lead to nonunion prognosis due to the size of
defects or unstable biomechanical properties, unfavourable
wound environment, suboptimal surgical technique, meta-
bolic factors, hormones, nutrition, and applied stress [2,3].
Bone grafts or substitute biomaterials are commonly used
therapeutic strategies for clinical bone surgery to fill the
bone defects for reconstructing large bone segments.
Although autografts are the current gold standard treatment
for bone defect regeneration [4,5], it still has disadvantages
such as limitation in donor supply [6], donor site pain, or
haemorrhage [7]. Other disadvantages of allograft are the
risk of immune-mediated rejection, the transmission of in-
fectious diseases and the negative effect on the mechanical
and biological properties of graft [8e11]. In order to over-
come the limitations associated with the current standard
treatment of bone grafts, there has been an increasing in-
terest in studying substitutes biomaterials, which are made
of naturally derived and/or synthetic materials, during the
past decades throughout the world [12e16]. The ideal bone
graft substitutes should be biocompatible, bioresorbable,
osteoconductive, osteoinductive, structurally similar to na-
ture bone, and easy or ready to use.
Prior to testing in human beings, an ideal bone substi-
tute should be tested both in vivo and in vitro, so as to
make sure that it works effectively and safely. Therefore,
to establish a suitable animal model is an indispensable
step when evaluating the mechanical property and
biocompatibility of bone substitute biomaterials. In this
review, we discuss the speciality of different species for
estimating bone defect substitute biomaterials in different
bone defect sites, such as crania [17e19], femora [20e22],
and ulna [23e25]. We evaluated the advantages and dis-
advantages of each species for estimating specific defects,
analysed and compared the similarities between animal
models and human clinical situations, and emphasised the
factors we need to consider when choosing animals.
General selection criteria
A number of animal test models, such as rat/mouse
[26e30], rabbit [31e34], dog [35e38], sheep [39e41], goat
[42e44], and pig [45e48], have been developed to simulate
human in vivo environment and physical conditions to test
the availability and comparability of bone substitute bio-
materials. In order to mimic various orthopaedic situations,
many defect sites have been explored, such as calvaria
[17e19], femora [20e22], and ulna [23e25]. A prerequisite
for such a model is that no spontaneous complete osseousregeneration of the created defects occurs during the
lifetime of the animals [49]. The critical size defect is
defined as the smallest osseous wound that does not heal
spontaneously over a long period of time. For practical
purposes, if there is no mineralised area of 30% after 52
weeks, there would never be complete bony regeneration.
Although the minimum size that renders a defect “critical”
is not well understood, it has been defined as a segmental
bone deficiency of a length exceeding 2e2.5 times the
diameter of the affected bone [11,50].
Various factors have to be considered for selecting a
specific animal species as a testing model. First and fore-
most, the chosen animal model should clearly demonstrate
both significant physiological and pathophysiological anal-
ogies in comparison to humans. Second, it must be
manageable to operate and observe a multiplicity of study
objects postsurgery over a relatively short period of time
[51]. Other selection criteria include costs for acquisition
and care, animal availability, acceptability to society,
tolerance to captivity, and ease of housing [52]. According
to the international standard, we should also consider the
size of the implant test specimens, number of implants per
animal, intended duration of the test, and potential spe-
cies’ differences with regard to biological responses [53].
The following are the most frequently used animal
models for creating bone defects to test conventional and
innovative biological biomaterials to be used as bone
substitutes.
Rabbits
Advantage and disadvantage of rabbit models
Rabbit is one of the most commonly used animal models,
and it ranks first among all the animals used for musculo-
skeletal research [54]. However, regarding the assessment
of multiple substitute biomaterials, the small size of rabbits
is the major drawback for studying orthopaedic implants.
However, it was reported that there were similarities in
bone mineral density and the fracture toughness of mid-
diaphyseal bone between rabbits and human [55]. Be-
sides, in comparison with other species, such as primates or
some rodents, rabbit has faster skeletal change and bone
turnover [56]. Rabbits are easily available, and easy to
house and handle. These characteristics make rabbits the
first choice when researchers develop animal model for the
in vivo test of a new bone substitute biomaterials.
Application of bone defect model for testing bone
substitute biomaterials in rabbits
In recent years, several rabbit models have been used to test
new bone substitute biomaterials. The most common im-
plantation sites include bilateral tibiae and distal femur
(Table 1). Walsh et al [57] investigated three commercially
available and clinically used b-tricalcium phosphate (TCP)
bone graft substitutes with the same chemistry (Vitoss,
Osferion, Chronos), but with various macro- and microscopic
characteristics, using a bilateral tibial metaphyseal defect
model onNewZealandwhite rabbits. Bilateral defects (5mm
wide and 15 mm long) spanning the metaphyseal and
Table 1 Rabbit bone defect models for testing bone substitute biomaterials.
Defect site Weight (kg) Defect size Substitute biomaterials
Tibiae 3e3.5 5 mm wide & 15 mm long [57], 6 mm in
diameter [60,61]; 5 mm in length [77]
b-TCP bone graft substitutes [57]; hydroxyapatite
60%/B-tricalcium phosphate 40% [60]; porous
titanium granules [61]; b-TCP, type I collagen,
& rhFGF-2 [77]
Femur 3e5 7  10 mm2 cylinder [59], 3 mm in diameter,
15 mm long [75]; 6 mm diameter  5 mm
cylinder [64,68]
Injectable calcium phosphate bone substitute [59];
PLGA/TCP/icaritin [75]; magnesium alloy AZ91D [63];
micro/ma-MCP [64]; CMMS/rhBMP-2 [65]; magnesium
calcium phosphate biocement [66]; magnesium
scaffolds [68]; magnesium silicate (m-MS) [67];
poly(epsilon-caprolactone)epoly(ethyleneglycol)e
poly(epsilon-caprolactone) composite scaffolds [67]
Calvaria 2.0e3 10 mm diameter  1.2 mm [78]; 9 mm
diameter [79]
Apatite-coated zirconia [78]; low-molecular-weight
silk fibroin [79]
Ulna 3.5e4 12 mm segment of midshaft ular [80];
15 mm segment of midshaft ular [13]
PLGA/tricalcium phosphate/icaritin/BMP-2
scaffolds [80]; BMP-2/PLGA-coated gelatin
sponge [13]
PLGA Z poly(lactic-co-glycolic acid); TCP Z tricalcium phosphate.
Bone defect animal models 97diaphyseal regions were created 3mmbelow the joint line in
the anteromedial cortex of the proximal tibia. It turns out
that all three b-TCP bone graft substitutes performed well in
this rabbit model. Young et al [58] developed an easily
accessible and reproducible, nonhealing, alveolar, 10 mm
“full-thickness” cylindrical defect removing both cortical
plates and the intervening trabecular bone and tooth roots
bone defect in the rabbit mandible. Gauthier et al [59] used
a cylindrical, 7e10 mm critical-size bone defect rabbit
model to investigate the efficiency of an injectable calcium
phosphate bone substitute for bone regeneration. The
critical-size bone defect rabbit model has been used suc-
cessfully to carry out a histomorphometric analysis of a new,
highly porous, biphasic calcium phosphate bone substitute
by Calvo-Guirado et al [60]. Delgado-Ruiz et al [61] also used
a critical-size tibiae defect rabbit model to test the behav-
iour of porous titanium granules, with and without mem-
branes being covered. The test result showed that the porous
titanium particles must be covered by a membrane, when
grafting larger defects. Chen et al [62] established a critical-
size bone defect model to test poly(lactic-co-glycolic acid)
(PLGA)/TCP/icaritin 3D printing scaffold on the ulnar site.
Protocol for developing steroid-associated
osteonecrosis rabbit model for testing bone
substitute biomaterials
Distal femur defect rabbit model has commonly been used
to test substitute biomaterials by a variety of researchers
[59,63e68]. Although distal femur is not the commonly
observed location of osteonecrosis in clinic, distal femur
defects are frequently observed after the removal of ma-
lignant bone tumours [69] and total knee replacement
[70e72]. Distal femur defects may lead to the failure of a
total knee arthroplasty if left untreated [73]. Therefore,
the use of a distal femur defect model is meaningful and
constructive in testing substitute biomaterials prior to
conducting human clinical trials. As the distal femoral
defect rabbit model is one of the most commonly usedanimal models to test substitute biomaterials, here we re-
view the surgical protocols for establishing steroid-
associated osteonecrosis (SAON) rabbit models with distal
femoral defect for testing bone substitute materials. SAON,
which would subsequently lead to subchondral joint
collapse, is caused by the frequent prescription of pulsed
steroids as a life-saving agent in a situation such as severe
acute respiratory syndromes. Core decompression is the
major treatment method for SAON in the early stage.
However, the nonunion bone defect that remained after
the surgery may lead to insufficient mechanical support of
the femur and result in joint collapse, seriously affecting
the prognosis. Therefore, the use of suitable bone substi-
tute materials to fill in the defect and provide a mechanical
support to the femur is essential for the process of SAON
bone defect repair. In order to test the substitute mate-
rials’ biocompatibility, mechanical properties, and avail-
ability, a model of SAON is necessary.
The protocol for establishing a SAON rabbitmodel is based
on our previously published work [74,75]. First of all, rabbits
should be in healthy condition, weigh 3.0e3.5 kg, and reach
an age of 28weeks, which is similar to the adult age of human
beings. Then, one injection of 10 mg/kg of lipopolysaccha-
ridewas given intravenously to the dopey rabbits. A day after
that, three injections of 20 mg/kg of methylprednisolone
were given intramuscularly at time intervals of 24 hours. Two
weeks later, 93% of the rabbits developed osteonecrosis and
none of them died during the procedure. This procedure is
considered to be more effective or efficient, with a lower
death rate compared with other published methods [76].
When the SAON rabbit model was established, we performed
core decompression in rabbits by drilling a 3.0 mm tunnel
transversely through the distal femora (Figure 1). Using this
model, we have tested the in vivo bone defect repairing
ability of a new bioactive PLGA/TCP composite scaffold
incorporating the phytomolecule icaritin [75].
Assessment of bone regeneration is a key step to esti-
mate the osteoconductive and osteoinductive abilities of
bone substitute biomaterials. It is also an essential step for
Figure 1 Surgical protocol for the establishment of core-decompression at the distal femur in a SAON rabbit model for im-
plantation of the PLGA/TCP/icaritin substitute biomaterial. (A) The surgical site is exposed by an operating scalpel. (B) A 3.0 mm
tunnel is drilled transversely through the distal femora by a trephine. (C and D) The biomaterial is implanted into the bone tunnel.
(EeG) Micro-CT three-dimensional image of the bone defect site. (H) X-ray image of the bone defect site. CT Z computed to-
mography; PLGA Z poly(lactic-co-glycolic acid); SAON Z steroid-associated osteonecrosis; TCP Z tricalcium phosphate.
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commonly used methodologies are histological analysis,
microcomputed tomography (micro-CT) analysis, mechani-
cal test analysis, radiograph analysis, sequential fluores-
cence labelling analysis, and dynamic contrast-enhanced
magnetic resonance imaging. Using dynamic contrast-
enhanced magnetic resonance imaging, we evaluated the
effectiveness of the SAON rabbit model [74]. It has also
been shown that using a SAON rabbit the in vivo osteoge-
neticability of PLGA/TCP/icaritin substitute biomaterial
could be tested successfully [75].
Rodents
Anatomical advantages and disadvantages of
rodents
As rodents are small in size and easy to handle, these are
one of the most commonly used animal models, considered
useful in preclinical studies for testing biomaterials as bone
substitutes, and regarded as one of the first-choice models
for in vivo test for regeneration of the bone tissue [81].
However, limitations of rodent models are also obvious.
Compared with other larger animals such as rabbits,
canine, and pigs, rodents have small-sized long bones and
thin and fragile cortices [82]. Besides, rodent models do not
show Haversian-type remodelling in the cortex, while lager
animals do.
Application of rodent bone defect model for testing
substitute biomaterials
Surgical implantation of substitute materials, such as b-
TCP, calcium phosphate, and collagen, has been commonlyconducted in rodents (Table 2). Kondo et al [83] investi-
gated the biocompatibility of highly purified b-TCP bone
graft substitutes using a rat femur defect model. Their
study suggested that purified b-TCP was biocompatible and
resorbable. In a study of 3D printing of composite calcium
phosphate and collagen scaffolds for bone regeneration, a
critical murine femur defect model was used to demon-
strate the in vivo properties of substitute biomaterials [84].
Ye et al [85] established a 4-mm-diameter calvaria critical-
size defect model in 6e8-week-old nu/nu mice. Based on
this model, the efficacy of iPSCs/silk scaffold in increasing
bone formation was revealed. Those rodent bone defect
models have all been used successfully to test the in vivo
osteoconductive and osteoinductive abilities of bone sub-
stitute materials.Protocol for establishing calvaria critical-size
defect nude mice model for testing bone substitute
biomaterials
Critical-size defects are considered the smallest wounds
established intraosseously, which cannot heal spontane-
ously during the lifetime of the animal [86]. In nude mice, a
defect of 3 mm in size has been reported to be necessary to
create a persisting femur bone defect [26]. Nude mice were
anaesthetised according to the recommended routines for
this species. A 4-mm-diameter calvaria critical-size defect
was created on each side of the cranium using a dental bur
attached to a slow-speed hand-piece with minimal invasion
of the dura mater. Critical-size defects were created,
which received implantation of substitute biomaterials
later [85].
Assessment of bone regeneration was performed later by
micro-CT scan and reconstruction, which showed that the
Table 2 Rodent bone defect models for testing new substitute biomaterials.
Defect site Animal Age/weight Defect size Substitute biomaterials
Distal femur F344/Fisher [83];
male Wistar rat [87]
8 wk [83]; 12e14 wk [87] 2 mm diameter & depth [83];
2 mm in diameter &
3 mm in length [87]
b-TCP bone graft substitutes
[83]; polymer containing
TGF-b1 [87]
Midfemur Female BALB/cJ [84];
male Fisher [88];
nude rat [89]
13e15 wk [84]; 253 g [88];
325e400 g [89]
2 mm in length [84];
5 mm in length [88];
5 mm in length [89]
Composite calcium phosphate
& collagen [84]; marrow cells
& porous ceramic [88];
BMPesilk composite
matrices [89]
Calvaria Nu/nu mice [85];
nude rat [90]
6e8 wk [85]; 12 wk [90] 4 mm diameter [85];
8 mm diameter [90]
iPSCs/silk scaffold [85]; PLGA
& adipose-derived stem
cells [90]
BMP Z bone morphogenetic protein; PLGA Z poly(lactic-co-glycolic acid)
Bone defect animal models 99majority of the calvaria defects were filled with a sub-
stantial amount of newly formed bone tissue in the defect
site treated with the SATB2-transduced iPSC implants 5
weeks postoperation. Histological analysis of bone regen-
eration further demonstrates radiographic results, indi-
cating that the SATB2-transduced group showed nearly
complete osseous closure of the defect [85].
Pigs
Anatomical advantage and disadvantage of pigs
Pigs are considered to be close representative models of
human bone regeneration processes with regard to bone
anatomy, morphology, healing capacity, remodelling, min-
eral density, and concentration [91,92]. Moreover, similar-
ities have been found in the femur cross-sectional diameter
and area between humans and pigs [93]. Besides, pigs also
have a lamellar bone structure similar to that of humans
[94]. However, pigs have a denser trabecular network,
which considered intricate, difficult to handle, noisy, and
aggressive; hence, pigs are often neglected in favour of
more amenable species such as sheep and goats [95e97].
Furthermore, the length of the tibiae and femora in pigs is
relatively small, which cannot meet the special implant
needs of humans. Pig was the animal of choice for critical-
size defect models to test bone substitute biomaterials
because its bone regeneration rate (1.2e1.5 mm/d) is
comparable to that of humans (1.0e1.5 mm/d) [49].Table 3 Pig bone defect models used to test bone substitute b
Animal Defect site Defect size
Porcine Craniofacial 10 mm diameter & 10 mm d
Go¨ttinger minipigs Tibial 11 mm diameter & 25 mm d
Minipig Parietal 2  4 cm2
Pig Orbital 2  2 cm2
BMP Z bone morphogenetic protein; PEG Z poly(ethyleneglycol).Commercial pigs are generally considered undesirable for
orthopaedic research because of their large growth rates
and very high body weight. However, the development of
miniature pigs and micropigs has overcome this problem to
some extent (Table 3).Application of pig bone defect models for testing
substitute biomaterials
Wehrhan et al [45] created a gene delivery method to in-
crease bone formation in a porcine craniofacial bone
defect model. The results showed that the gene delivery
method formed more new bone in the defect site. Riegger
et al [98] created circumscribed cylindrical bone defects
of 11 mm diameter and 25 mm depth without penetration
of the lateral cortex in the medial plateau of the tibia of
16 minipigs. The defect model was created to test the
in vivo effect of the granular calcium phosphate compos-
ites and bone marrow aspiration concentrate. They found
that there was a significant correlation between the two
detective methods, showing that multidetector CT could
be a promising tool for monitoring bone healing. A minipig
infant model with craniofacial bone defect was created to
test the in vivo effect of autologous bone grafts and bone
morphogenetic protein-7 (rhBMP-7) by Springer et al [48].
Rohner et al [99] used a pig orbital defect model to show
the in vivo efficacy of bone marrow-coated poly-
caprolactone scaffolds. Their studies showed that this
bone marrow-coated 3D polycaprolactone scaffold is aiomaterials.
Substitute biomaterials
epth HA/TCP, PEG membrane, BMP-2 [45]
epth Granular calcium phosphate, bone marrow aspiration
concentrate; platelet-rich plasma [98]
Particulate iliac bone graft, rhBMP-7 composite [48]
Bone-marrow-coated polycaprolactone scaffolds [99]
100 Y. Li et al.promising substitute biomaterial for enhancing bone
regeneration.
Protocols for developing a porcine craniofacial
bone defect model and testing substitute
biomaterials
The porcine craniofacial bone defect model is used widely
for testing bone substitute biomaterials. A commonly used
protocol for developing a porcine craniofacial bone defect
model and testing substitute materials was reported by
Wehrhan et al [45]. Briefly, after anaesthetising domestic
pigs and exposing the skull, nine defects of 10 mm diameter
and 10 mm depth were created on it. Three testing groups,
i.e., HA/TCP covered by poly(ethyleneglycol) (PEG) mem-
brane, HA/TCP mixed with PEG matrix, and HA/TCP mixed
with BMP-2 transfected hFOB cells and PEG matrix, were
filled in three out of nine defects. The remaining six defects
were filled with HA/TCP. After 2 weeks, 4 weeks, and 12
weeks, the animals were sacrificed and the os frontale was
harvested for the following histological and immunohisto-
chemical analyses.
Sheep/goats
Advantage and disadvantage of sheep or goats
It has been reported that adult sheep offer the advantage
of possessing a body weight similar to adult humans, and
having long bones of dimensions suitable for testing human
implants and prostheses [96], which is not possible in small
species such as rabbits and dogs. Sheep bones have similar
macrostructure to human bones, but histologically, the
bone structure of sheep is different from that of humans. In
sheep, bone consists predominantly of the primary bone
structure [100] in comparison with the largely secondary
bone structure of humans [101]. Secondary bone remodel-
ling in sheep does not take place until an average age of
7e9 years [96], while at 3e4 years of age they have a
plexiform bone structure comprising a combination of
woven and lamellar bones within which vascular plexuses
are sandwiched [51]. Mature sheep have a significantly
higher trabecular bone density and subsequently greater
bone strength when compared to humans [51,102]. How-
ever, differences may change with location. Some re-
searchers argue that sheep are still valuable models for
human bone turnover and remodelling activity, although
differences in bone structure were defined [103e105].
Sheep are shown to have a larger amount of bone ingrowth
than humans; this is probably due to the greater amount of
cancellous bone in the distal femur of sheep compared with
humans [106].
Application of sheep bone defect models for testing
substitute biomaterials
Maissen et al [107] used an ovine segmental defect model
to investigate the influence of rhTGFb-3 on mechanicaland radiological parameters of a healing bone defect.
The osteogenesis and remodelling effects of a biphasic
synthetic bone graft material (Genex Paste; Bio-
composites, Staffordshire, England), composed of calcium
sulphate and b-TCP, on the healing of a sheep vertebral
defect model was described in a canine model by Yang
et al [39]. Zhu et al [40] developed a sheep vertebral
bone defect model to evaluate the new bioactive mate-
rials and assessed the feasibility of the model in vivo.
Reichert et al [41] developed a preclinical ovine model
for tibial segmental bone defect repair by applying bone
tissue engineering strategies. Lippens et al [42] used a 6-
mm-size unicortical tibia defect goat model to evaluate
the in vivo bone formation effect of an injectable poly-
merisable pluronic F127 hydrogel derivative combined
with autologous mesenchymal stem cells. Kobayashi et al
[108] used a 8-mm-diameter and 15-mm-deep sheep
vertebral bone void model to investigate the histological
properties of three formulations of calcium sodium
phosphosilicate.
Protocols for developing a sheep tibia defect model
for testing bone substitute biomaterials
The sheep tibia defect model has been used to test bone
substitute by many researchers [41,42,107]. Here we re-
view the protocol of an 18-mm-long mid-diaphysis tibia
defect created in sheep for testing substitute materials and
autologous bone graft. The defect was created in a 4e5-
year-old sheep model and stabilized with a unilateral
external fixator. The implant to the defects was divided
into four groups. Assessment of in vivo stiffness was per-
formed every week in a 4-week period by a custom-made
device [107]. The radiology result revealed that only the
bone graft group showed obvious recovery. Radiographic as
well as computer tomographic evaluation was used to
assess bone regeneration of the defect side.
Conclusion
Animal models play an indispensable role in testing bone
substitute biomaterials for understanding their osteo-
conductivity, biocompatibility, mechanical properties,
degradation, and interaction with host tissues. In this re-
view, we summarised the most commonly and successfully
used animal models, and the protocols that may be used as
references to establish relevant preclinical experimental
animal model(s) for testing both biosafety and treatment
efficacy of bone substitutes (Table 4). After reviewing >100
publications about in vivo tests of biomaterials, we
conclude that most authors fail to discuss the reason for
choosing the animal model that they established and the
clinical indication that they are stimulating. Although no
animal model is perfect to simulate clinical conditions, we
recommend that animal models should be established
based on clinical indications. Finally, anaesthesia practice
and specific surgical protocol should be included in the
publications so as to make sure that animal welfare is well
established.
Table 4 Summary of advantages and disadvantages of different bone defect animal models.
Animal
species
Bone defect site Advantages Disadvantages
Pig Craniofacial Bone anatomy, morphology, healing capacity,
& remodelling similar to humans; similar bone
structure with respect to bone mineral density
& concentration; a lamellar bone structure
Denser trabecular network, intricate & difficult
to handle, noisy & aggressive, shorter tibiae
& femur, large growth rates, & very high
body weight
Sheep Tibiae Body weight similar to adult humans, easy to
handle & house, relatively inexpensive,
available in large numbers
Significantly higher trabecular bone density
& subsequently greater bone strength, larger
amount of bone ingrowth than humans
Rabbit Tibiae femur Easy to handle & small size, reaching skeletal
maturity shortly after sexual maturity
at w6 mo of age
Small size; differences in bone anatomy, such
as size & shape of the bones & also in loading;
faster skeletal change & bone turnover
Rodent Femur calvaria Easy to handle & small size, life span suitable
for postsurgery observation
Small-sized long bones & thin & fragile cortices,
no showing of Haversian-type remodelling
in the cortex
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